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Abstract
Objectives
Variants in the neuroﬁbromatosis type 1 (NF1) gene are not only responsible for the NF1
cancer predisposition syndrome, but also frequently identiﬁed in cancers arising in the general
population. While germline variants are pathogenic, it is not known whether those that arise in
cancer (somatic variants) are passenger or driver variants. To address this question, we sought
to deﬁne the landscape of NF1 variants in sporadic cancers.
Methods
NF1 variants in sporadic cancers were compiled using data curated on the c-Bio database and
compared with published germline variants and Genome Aggregation Database data. Pathogenicity was determined using Polyphen and Sorting Intolerant From Tolerant prediction tools.
Results
The spectrum of NF1 variants in sporadic tumors diﬀer from those most commonly seen in
individuals with NF1. In addition, the type and location of the variants in sporadic cancer diﬀer
from germline variants, where a high proportion of missense variants were found. Finally, many
of the sporadic cancer NF1 variants were not predicted to be pathogenic.
Discussion
Taken together, these ﬁndings suggest that a signiﬁcant proportion of NF1 variants in sporadic
cancer may be passenger variants or hypomorphic alleles. Further mechanistic studies are
warranted to deﬁne their unique roles in nonsyndromic cancer pathobiology.
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Neuroﬁbromatosis type 1 (NF1) is a cancer predisposition
syndrome aﬀecting 1 in 3,000 individuals worldwide (OMIM:
162200). While individuals with NF1 frequently present with
pigmentary abnormalities, there is also a higher incidence of
both benign and malignant tumors, including peripheral nerve
sheath tumors, gliomas, pheochromocytoma, and breast
cancer. In addition, the NF1 gene is one of the most frequently mutated genes in cancers of the general population,
with variant frequencies ranging from 15% to 70%.1 While
germline variants in individuals with NF1 are assuredly disease causing, it is unclear whether somatic variants identiﬁed
in the setting of sporadic cancer represent pathogenic variants
important for neoplastic progression or passenger variants
with little eﬀect on oncogenesis. Herein, we compared the
NF1 variant spectrum in patients with NF1 (germline) with
those detected in sporadic cancers.

Methods
Somatic NF1 variants in sporadic cancers were assembled from
cBioPortal.2 Duplicate samples, deﬁned as having the same
sample identiﬁcation number and variant, were eliminated.
Cancer types harboring fewer than 13 NF1 variants were excluded. NF1 gene variant type and location were compared
with all published germline NF1 variants from patients known
to have NF1 based on clinical diagnostic criteria3,4 and Genome Aggregation Database (gnomAD) data.5 To evaluate
variant location, the neuroﬁbromin protein was divided into
tertiles, representing amino acids 1–939, 940–1878, and
1879–2818.3 Pathogenicity was determined using Polyphen
and Sorting Intolerant From Tolerant. Two-sample t tests were
used to compare the percentage of germline and sporadic
variants in each neuroﬁbromin tertile. The Fisher exact test was

Figure 1 Percentage of NF1 Variants in Sporadic Cancers

Bar chart depicting the percentage of NF1 variants found in each cancer type. The percentages were calculated by dividing the number of samples harboring
an NF1 variant by the total number of cancer samples in each cancer type. The orange bars denote those cancers more prevalent in individuals with NF1. NF1 =
neurofibromatosis type 1.
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used to compare the frequency of germline and sporadic variant
types. Statistical signiﬁcance was set at p < 0.05. R Script
adapted from Plot Protein was used to map variants onto the
NF1 isoform P21359-2 (NP_000258.1).6 Additional data and
references are provided in eTables 1 and 2 and eReferences
(links.lww.com/NXG/A533).
Data Availability
Data were deidentiﬁed and available in publicly accessible databases or from published reports, not requiring institutional
review board approval or new data deposition.

Results
Thirty-eight diﬀerent sporadic cancers, harboring 2,176 somatic NF1 variants, were compared with 1,161 germline
variants, including 298 NF1 variants from patients with
known NF1 and 863 germline polymorphic variants from
gnomAD. First, we found that cancer types with the highest
frequency of NF1 variants were not those commonly overrepresented in people with NF1 (Figure 1). As such, melanoma and uterine carcinoma had the highest percentages of

NF1 variants while those cancers seen in individuals with NF1
ranged from <1% (breast cancer) to 21% (glioblastoma).
Second, although there were fewer NF1 variants in the third
tertile of the NF1 gene in individuals with NF1 (p = 0.047), as
previously reported in children (12%)3 and adults with other
NF1-associated brain tumors (11%)7 (Figure 2A), NF1 variants were evenly distributed along the NF1 coding sequence
in sporadic cancers (Figure 2B). Similarly, in previous studies
examining NF1-associated brain tumors (low-grade and highgrade gliomas), somatic variants were also spread broadly
throughout the NF1 gene, while the germline variants were
found to have a slight bias toward the 59 end of the gene and
did not cluster in speciﬁc domain regions.6,7 Using synonymous variants as a control, there were no signiﬁcant diﬀerences in the distribution of germline and sporadic variants
(Figure 2, A and B). Third, while NF1 germline variants were
mainly nonsense and frameshift variants (61%), sporadic
cancer NF1 variants were mostly missense variants (48%)
(Figure 2C). A visual depiction of the location and frequency
of the sporadic and germline missense variants shows this
diﬀerence in NF1 variant proﬁles (Figure 3A). Despite comprising half of all sporadic cancer variants, most missense NF1
variants were not predicted to be pathogenic, with only 1.4%

Figure 2 Comparison of Variant Distribution and Type in Patients With NF1 vs Sporadic Cancers

(A) The percentage of missense and loss-of-function NF1 variants found in each tertile of the NF1 protein (neurofibromin) for individuals with NF1 (white bars)
relative to sporadic cancers (gray bars). Error bars represent standard errors of the mean (2-sample t test). The germline variants include data from 3 sources
of NF1 germline variants.3-5 Individual points represent variants from each curated list of germline variants or sporadic cancer type. (B) The percentage of
germline (white bars) and somatic (gray bars) synonymous variants located in each tertile of the NF1 protein (Fisher exact test). (C) The percentage of each type
of NF1 variant, grouped into germline (white bars) and somatic (gray bars) pairs (Fisher exact test). NF1 = neurofibromatosis type 1.
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Figure 3 Distribution and Pathogenicity of Missense NF1 Variants

(A) Visual representation of missense NF1 variants in sporadic cancers (circles; somatic variants) and NF1 patients (triangles; germline variants), with the numbers and
locations arrayed along the NF1 protein (neurofibromin) coding sequence. Color corresponds to the number of times each variant occurred (y-axis number colors).
Vertical lines indicate the boundaries of the neurofibromin tertiles. Known structural motifs are depicted including the CSRD, cysteine-serine-rich domain; TBD, tubulin
binding domain; GRD, GTPase-activating protein-related domain; SBD, syndecan binding domain; Sec14, Sec14 domain; PH, pleckstrin homology domain; CTD,
carboxy-terminal domain. (B) Recurrent missense variants (N) in sporadic cancers are listed with their allele frequencies, predicted pathogenicity (using Polyphen and
SIFT), and presence in gnomAD. gnomAD = Genome Aggregation Database; NF1 = neurofibromatosis type 1l SIFT = Sorting Intolerant From Tolerant.

of all somatic variants estimated to be pathogenic. In addition,
only 3% of all sporadic cancer NF1 missense variants were
predicted to be pathogenic. Further analysis revealed that 16
missense variants occurred 4 or more times (Figure 3B),
where 11 (69%) were predicted to be pathogenic.

Discussion
Taken together, these results demonstrate that NF1 variants in
sporadic cancers diﬀer both in location and type relative to
4
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germline variants from individuals with NF1, and that cancers
with the largest frequency of NF1 variants were not the tumors
most prevalent in the setting of NF1 clinical disease. Of interest,
the preponderance of missense variants in sporadic cancers
raises the intriguing possibility that some of these NF1 variants,
especially missense variants, could represent nonpathogenic
“passenger”, or hypomorphic, variants. However, a majority of
recurrent missense mutations were predicted to be pathogenic.
Future studies that aim to deﬁne the eﬀects of these variants on
neuroﬁbromin structure, protein interactions, and function are
required to determine their signiﬁcance to oncogenesis.
Neurology.org/NG
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